ALK and non-small cell lung carcinoma: Meanwhile, the most recent guidelines recommend that all patients with advanced NSCLC—both non-squamous and squamous—should be screened not only for EGFR, ALK, and PD-L1 but also for ROS1 and BRAF mutations.